Phase II Trial of Neo-adjuvant Temozolomide Prior to Combined Temozolomide and Concurrent Accelerated Hypofractionated External Beam Radiotherapy Followed by Adjuvant Temozolomide in Patients With Newly Diagnosed Glioblastoma Multiforme

Inclusion Criteria

• •Age: 18 years or older
• •Histological confirmation of supratentorial GBM
• •KPS \> 60
• •Neurological function 0 or 1
• •Adequate bone marrow as defined below:
• •absolute neutrophil count (ANC) \> 1500 cells/mm3
• •platelets \> 100,000 cells/mm3
• •hemoglobin \> 10g/dl
• •Adequate renal function as defined below:
• •BUN \< 25mg/dl within 14 days prior to study registration
• •creatinine of 63 to 103 umol/L within 14 days prior to study registration
• •Adequate hepatic function as defined below:
• •Bilirubin of 3 to 21 umol/L within 14 days prior to study registration
• •ALT \& AST \< 3xnormal range within 14 days prior to study registration
• •Neoadjuvant TMZ to start within 3 weeks of surgery/biopsy if no resection was deemed feasible
• •A diagnostic contrast-enhanced MRI or CT scan of the brain must be performed preoperatively and postoperatively.
• •History, physical and neurological examination within 14 days prior to study registration.
• •For females of child-bearing potential, negative pregnancy test within 72 hours prior to starting TMZ.
• •Able to sign an informed study-specific consent